🚀 Gate Square “Gate Fun Token Challenge” is Live!
Create tokens, engage, and earn — including trading fee rebates, graduation bonuses, and a $1,000 prize pool!
Join Now 👉 https://www.gate.com/campaigns/3145
💡 How to Participate:
1️⃣ Create Tokens: One-click token launch in [Square - Post]. Promote, grow your community, and earn rewards.
2️⃣ Engage: Post, like, comment, and share in token community to earn!
📦 Rewards Overview:
Creator Graduation Bonus: 50 GT
Trading Fee Rebate: The more trades, the more you earn
Token Creator Pool: Up to $50 USDT per user + $5 USDT for the first 50 launche
Lianhuan Pharmaceutical: The LH-1801 project faces significant uncertainties at multiple critical stages from successful clinical trials to final market launch and profitability.
Jin10 data reported on July 8th that Lianhuan Pharmaceutical issued an announcement regarding abnormal fluctuations in stock trading. The LH-1801 project clinical trial adopts a non-inferiority design, and there is significant uncertainty regarding whether the target can ultimately be achieved. The LH-1801 project faces significant uncertainties in multiple key segments from successful clinical trials to final market launch and profitability. The LH-1801 project is currently still in the R&D stage and is expected to not have a significant impact on the company’s operating income and performance for a considerable period of time.